Myalgic Encephalomyelitis / Chronic Fatigue Syndrome

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a severe, chronic, multi-system neuroimmune disease affecting an estimated 0.89% to 2.5% of the global population.Characterized by profound post-exertional malaise, unrefreshing sleep, cognitive dysfunction,and autonomic dysregulation, ME/CFS represents one of the most disabling chronic conditionsin modern medicine. Despite affecting millions worldwide, the disease has historically sufferedfrom underfunding, dismissal by medical professionals, and classification as a syndromerather than a disease with identifiable pathophysiology. The February 2024 NIH deep phenotyping study fundamentally transformed this landscapeby demonstrating specific biological abnormalities: decreased brain activity in effort-relatedneural circuits, exhausted T-cell populations, chronic B-cell activation deficits, and depletedcatecholamine levels in cerebrospinal fluid. These findings conclusively established ME/CFS as a systemic biological disease with measurable immune, neurological, and metabolicdysfunction. This comprehensive documentation synthesizes current research across clinical presentation,pathophysiological mechanisms, treatment approaches, research evidence, and quantitativemodeling. The work integrates findings from hundreds of peer-reviewed sources spanningenergy metabolism dysfunction, immune exhaustion, neuroinflammation, endocrine dysregu-lation, cardiovascular abnormalities, gut-brain axis disruption, and genetic-epigenetic factors.Part I (Chapters 1–5) provides detailed clinical characterization of core and additionalsymptoms, the evolution of diagnostic criteria from Fukuda through the Canadian Consen-sus and International Consensus Criteria, and disease course variations from mild to verysevere presentations including severity-specific phenotyping. Part II (Chapters 6–16) examinesestablished and hypothetical pathophysiological mechanisms across eleven chapters coveringmitochondrial dysfunction, immune exhaustion, neuroinflammation, endocrine dysregula-tion, cardiovascular and autonomic failure, gut-microbiome disruption, genetic and epigeneticfactors, integrative multi-system models, speculative mechanistic hypotheses with falsifiablepredictions, symptom-producing mechanisms, and a capstone causal hierarchy analysis classi-fying all mechanisms as trigger-capable root causes, amplifiers, or downstream consequences.Part III (Chapters 14a–19) opens with urgent action protocols for severe and very severe cases,followed by pediatric-specific management for both housebound and ambulatory children,then documents symptom-based management, medications targeting underlying mechanisms,supplement regimens, lifestyle interventions, emerging therapies, and integrative personal-ized approaches. Part IV (Chapters 20–25b) synthesizes biomarker research, clinical trialoutcomes, mechanistic studies, epidemiological patterns, research controversies, translationalfindings, research infrastructure proposals, and a set of fully specified proposed studies withexplicit hypotheses and trial designs. Part V (Chapters 26–33) develops formal mathematicalmodels of disease dynamics using ordinary differential equation systems, presenting energymetabolism models, immune system dynamics, neuroendocrine and autonomic regulation, integrated multi-system coupling, temporal evolution with tipping-point dynamics, predictive clinical applications for pacing optimization and treatment selection, and a formal causal hierarchy analysis (Chapter 33) that subjects the root cause–amplifier–consequence classification to mathematical testing using sensitivity analysis, bifurcation theory, and the separatrix nudging framework. Nine appendices provide reference material: a glossary of medical and scientific terms, abbre-viations, diagnostic tools and assessment scales, patient resources, mathematical derivationssupporting Part V, supplement protocols, a research synthesis, an annotated bibliography oflandmark studies, and a registry of ongoing and planned ME/CFS studies. Methodologically, this work uses a structured epistemic classification system distinguishingachievements (high-certainty findings from replicated studies), hypotheses (certainty ≥ 0.45,requiring validation), speculations (certainty < 0.45, exploratory), predictions (testable claimsfor future research), warnings (critical limitations and contraindications), and recommenda-tions (evidence-based guidance requiring physician review). Evidence quality is systematicallyclassified as high, medium, or low certainty based on sample size, peer-review status, repli-cation, and methodological rigor. A cross-document hypothesis registry tracks all speculativecontent with falsifiability assessments. This documentation serves multiple audiences: researchers seeking comprehensive mechanis-tic understanding and quantitative modeling frameworks, clinicians requiring evidence-basedtreatment protocols with dosing guidance and contraindication awareness, patients andcaregivers needing accessible explanations of symptoms and management strategies, andadvocates working toward recognition, funding, and medical education reform. The workis released under the Creative Commons Attribution 4.0 International License to maximizeaccessibility and enable derivative works. Written by a software architect and researcher with degrees in industrial engineering and man-agement sciences, this documentation applies systems thinking, computational analysis, andfirst-principles reasoning to ME/CFS pathophysiology while maintaining epistemic humilityabout the substantial uncertainties remaining in the field. The author explicitly disclaimsmedical expertise and emphasizes that all content represents literature synthesis and personalexperience documentation, not clinical advice. All treatment decisions must be made inconsultation with qualified healthcare providers. ME/CFS research is at a critical inflection point. The biological validation provided by recentNIH and international studies, combined with shared research agendas driven by LongCOVID parallels, offers unprecedented opportunity for mechanistic discovery and therapeuticdevelopment. This document aims to accelerate progress by organizing scattered findings intoan accessible, comprehensive reference while identifying critical knowledge gaps requiringfocused investigation.